Healthcare / BiotechnologyShanghai
$14.98
-0.54 (-3.48%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 21%
FCF escenarios
weak_data · normalized FCF $-82.1M · quality 60.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
30/100
D
Piotroski
6/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.3B
P/E
N/A
•EV/EBITDA
63.0x
↑ROE
-2.0%
↓Gross Margin
66.8%
↑Debt/Equity
0.58
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
+43.3%
FCF CAGR
—
FCF margin
-4.2%
FCF / Net income
1.55x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $719.2M · net income $-19.5M · FCF $-30.3M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $719.2M | $719.2M | $417.8M | $411.4M | $244.2M |
| Net Income | $-19.5M | $-19.5M | $-141.2M | $-76.1M | $-124.1M |
| EBITDA | $95.8M | $95.8M | $-97.5M | $-35.2M | $-100.6M |
| EPS | -0.05 | -0.05 | -0.34 | -0.18 | -0.30 |
| Gross Margin | 66.8% | 66.8% | 54.9% | 46.2% | 42.9% |
| Operating Margin | 8.5% | 8.5% | -25.5% | -16.6% | -46.8% |
| Net Margin | -2.7% | -2.7% | -33.8% | -18.5% | -50.8% |
| Balance Sheet | |||||
| Debt/Equity | 0.58 | 0.58 | 0.50 | 0.37 | 0.17 |
| Current Ratio | 1.50 | 1.50 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $-30.3M | $-30.3M | $-82.1M | $-237.4M | $-232.9M |
| Returns | |||||
| ROE | -2.0% | -2.0% | -14.4% | -6.8% | -10.3% |
| Valuation | |||||
| EV/EBITDA | 63.03 | 63.03 | — | — | — |
| P/B | 6.07 | 6.07 | 3.18 | 4.54 | 3.97 |
| Growth & Yield | |||||
| Revenue Growth | 72.1% | 72.1% | 1.6% | 68.4% | — |
| EPS Growth | 85.3% | 85.3% | -88.9% | 40.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+34.8%
Start / end P/E
n/dx → n/dx
EPS bridge
-0.34 → -0.05
Residual
+34.8%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.